Systemic Therapy With a Loco-regional Treatment in Patients With Locally Advanced Pancreat
Background Pancreatic cancer is one the leading causes of cancer-related death in Canada. Approximately 40 percent of patients with pancreatic cancer present with locally advanced pancreatic cancer and are not candidate for curative surgery. The optimal management of patients with locally advanced pancreatic cancer rem
| Condition(s) | Locally Advanced Pancreatic Cancer, Irreversible Electroporation |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | Background Pancreatic cancer is one the leading causes of cancer-related death in Canada. Approximately 40 percent of patients with pancreatic cancer present with locally advanced pancreatic cancer and are not candidate for curative surgery. The optimal management of patients with locally advanced pancreatic cancer remains unknown. Most patients are treated with chemotherapy alone and role of local treatment such as radiation is not well defined. Other conventional ablative therapies such as thermal ablation and cryoablation have limited role in locally advanced pancreatic cancer due to the risk of collateral damage to the adjacent structures. Irreversible electroporation (IRE) is a novel non-thermal ablation technology that does not cause injury to nearby blood vessels, ducts, and bowel a |
| Who can participate | Inclusion Criteria: Adult patients with biopsy-proven locally advanced pancreatic adenocarcinoma who are candidates for combination chemotherapy as determined by treating oncologists. Exclusion Criteria: 1. Pregnancy 2. Metastatic pancreatic cancer 3. Another active second primary cancer with the exception of squamous cell carcinoma of the skin or an in situ cancer. |
| Sex | All |
| Lead sponsor | University of Saskatchewan |
| Locations | Regina, Saskatchewan, Canada; Saskatoon, Saskatchewan, Canada |
| Start date | 2025-05-01 |
| NCT ID | NCT04276857 |
| Official listing | https://clinicaltrials.gov/study/NCT04276857 |